Clinical Trial Update: Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

TYK Medicines is conducting a Phase 1/2 study of TYK-00540 tablets in HR-positive, HER2-negative advanced breast cancer; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TYK-00540 (TYK-00540)

Snippet

Sponsor: TYK Medicines, Inc | Conditions: HR-positive, HER2-negative Advanced Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING